Alimera Sciences Inc

Alimera Sciences — Technical Presentation (August 2011)

20 slides from Alimera Sciences's technical presentation, Aug 25, 2011

  1. Slide 1: ILUVIEN FAME Study: Fluocinolone Acetonide in Diabetic Macular Edema 36-Month Results

    ILUVIEN(r) FAME(tm) Study: Fluocinolone Acetonide in Diabetic Macular Edema 36-Month Results^Single Insert Outcomes

  2. Slide 2: Financial Disclosures

    Financial Disclosures Consultant /Speaker: Alcon, Allergen, Genentech-Roche, Pfizer, NovartisConsultant : Regeneron, Thrombogenics, iCo, AlimeraRetina Vitreous Associates has performed and received compensation for doing research for Alcon, Allergen, Genentech, Regeneron, Ophthotec, Novartis, GSKI h

  3. Slide 3: Status: off label use discussion

    STATUS I will be discussing the off label use of an extended release fluocinolone acetonide implant

  4. Slide 4: ILUVIEN Drug Delivery Insert

    Nonbioerodible cylindrical tube; 3.5 mm long, 0.37 mm in diameterInjected through a self-sealing wound via 25-gauge proprietary inserter Two doses studied; 0.2 µg and 0.5 µg of fluocinolone acetonide (FAc) per day ILUVIEN Drug Delivery Insert ILUVIEN(r) is a registered trademark of Alimera Sciences.

  5. Slide 5: FAME Study Design

    0 6 12 18 24 30 36 ILUVIEN 0.2 µg/d FAc (n = 376) 0.5 µg/d FAc (n = 395) Control: sham injection (n = 185) FAME Study Design Additional laser therapy allowed after week 6a Retreatment any time after month 12 (if eligibleb) Study ends N = 956Randomization 2:2:1 Primary readout Patients with DME and:^

  6. Slide 6: Percentage of Patients With ≥15-Letter Improvement Over Baseline

    (CHART) Months Patients, % 28.7% 18.9% P = .018 Primary readout 28.7% 16.2% P = .002 Percentage of Patients With ^ 15-Letter Improvement Over Baseline Campochiaro P, et al. Ophthalmology. 2011;118:626-635.Alimera Sciences. Data on File.

  7. Slide 7: Cataract-Related Events and IOP-Related Events

    Cataract-Related Events Cataract-Related Events AE, adverse event; IOP, intraocular pressure. a Phakic patients only.b For a minimum of 7 days. Subjects, %(Study Eye) Control(n = 185) 0.2 µg/d FAc (n = 375) 0.5 µg/d FAc(n = 393) IOP > 30 mm Hg 4.3 18.4 22.9 Any IOP-lowering medsb 14.1 38.4 47.3 Trab

  8. Slide 8: ILUVIEN Single-Insert Efficacy

    ILUVIEN Single-Insert Efficacy

  9. Slide 9: Study, Laser, and Off-Protocol Treatments

    Study, Laser, and Off-Protocol Treatments Control(n = 185) 0.2 µg/d FAc(n = 376) 0.5 µg/d FAc(n = 395) Study treatments (sham injection or ILUVIEN insert) Study treatments (sham injection or ILUVIEN insert) Study treatments (sham injection or ILUVIEN insert) Study treatments (sham injection or ILUVI

  10. Slide 10: Percentage of Patients With ≥15-Letter Improvement Over Baseline

    (CHART) Months Patients, % 28.7% Percentage of Patients With ^ 15-Letter Improvement Over Baseline, 0.2 ^g/d FAc 36.7% 38.3% 43.1%

  11. Slide 11: ILUVIEN Single-Insert IOP Changes

    ILUVIEN Single-Insert IOP Changes

  12. Slide 12: Aqueous Concentration of FAc and Mean IOP

    Relationship Between Aqueous Concentration of FAc and Mean IOP in Patients Receiving a Single 0.5 ^g/d FAc Insert FAc Concentration +- SEM, ng/mL Months (CHART) (CHART) Months IOP, mm Hg FAc Concentration in Human Aqueous Humor Mean Change From Baseline IOP Data on file. Alimera Sciences.

  13. Slide 13: Reversibility of IOP Changes: Patient Case

    Reversibility of IOP Changes: Patient Case Reversibility of IOP Changes: Patient Case FAc insert removed IOP, mm Hg Days 25 days

  14. Slide 14: Mean Change from Baseline IOP in Study Eye

    (CHART) Months IOP, mm Hg Mean Change from Baseline IOP in Study Eye in Patients With 1 Insert Data on file. Alimera Sciences.

  15. Slide 15: Time to First IOP-Lowering Medication With Single Study Treatment

    Time to First IOP-Lowering Medication With Single Study Treatment Exposure Single Study Treatment Exposure Single Study Treatment Exposure Only patients who required IOP-lowering medication. Months From Initial Treatment Patients, %

  16. Slide 16: IOP-Lowering Medications With a Single Study Treatment, by Year

    IOP-Lowering Medications With a Single Study Treatment Exposure, by Year Patients, % (CHART) Years After First Study Treatment Number of IOP-lowering medications 1 New and ongoing IOP-lowering medications by year. 2 3

  17. Slide 17: IOP-Related Events With Single Study Treatment by Year

    IOP-Related Events With Single Study Treatment Exposure by Year, Study Eye Patients, % (CHART) Year 1 2 3 New reports by year.

  18. Slide 18: 15-Letter Gain in BCVA Based on IOP Status

    15-Letter Gain in BCVA at Months 33 and 36 Based on IOP Status Patients, % n = 118 202 200 6 55 68 Data on file. Alimera Sciences. Month 33 Month 36 n = 119 215 209 7 55 67

  19. Slide 19: Conclusions

    Conclusions ILUVIEN significantly increases the percentage of patients who achieve 3-line or greater improvement in BCVA in a DME population previously treated with at least one laser with center-involved edemaApproximately three-fourths of these patients were able to achieve significant visual bene

  20. Slide 20: Acknowledgments

    Acknowledgments The FAME Study GroupThe 956 patients and their caregivers who participated in the study101 sites, investigators, coordinators and staff in North America, Europe, and IndiaWisconsin Fundus Photograph Reading CenterBernie McCary - Endothelial Cell Count Reading CenterCROs: Chiltern, EM

Alimera Sciences — Technical Presentation (August 2011) on 6ix